Lee-Wong Mary, Dayrit Francis M, Kohli Anita R, Acquah Samuel, Mayo Paul H
Division of Allergy/Immunology, Beth Israel Medical Center, Albert Einstein College of Medicine, 350 East 17th Street, 18 BH22, New York, NY 10003, USA.
Chest. 2002 Oct;122(4):1208-13. doi: 10.1378/chest.122.4.1208.
To investigate whether, after 48 h of IV treatment with corticosteroids, the use of high-dose inhaled flunisolide is as effective as systemic corticosteroids in adults hospitalized for a severe asthma exacerbation.
Randomized, double-blind, placebo-controlled study.
Inpatient, an urban teaching hospital medical ward; outpatient, asthma clinic affiliated with the hospital.
Forty patients aged 18 to 55 years with asthma exacerbation requiring hospitalization.
Inhaled flunisolide via metered-dose inhaler (250 micro g per activation) eight puffs bid compared to systemic corticosteroids alone, following eight doses of IV corticosteroids.
Peak expiratory flow rate (PEFR), FEV(1), and symptom scores were recorded on day 1 (at presentation to the emergency department) and day 7, at an outpatient follow-up visit. From day 1 to day 7, mean PEFR increased from 190 to 379 L/min in the flunisolide group, and from 207 to 347 L/min in the systemic corticosteroids group (p = 0.95; 95% confidence interval [CI], - 66.3, infinity ). Mean FEV(1) increased from 1.6 to 2.3 L in the flunisolide group, and from 1.4 to 2.1 L in the systemic corticosteroids group (p = 0.33; 95% CI, - 21.7, infinity ). Changes in symptom scores were - 0.7 in the flunisolide group and - 0.9 in the systemic corticosteroids group (p = 0.39; 95% CI, - 0.4, infinity ). Hospital readmission rates on day 7 were zero for both groups.
High-dose inhaled corticosteroids are as effective as systemic corticosteroids during a 7-day period following admission to the hospital for severe asthma.
探讨在接受48小时静脉注射皮质类固醇治疗后,高剂量吸入氟尼缩松对因严重哮喘急性发作住院的成年人是否与全身用皮质类固醇同样有效。
随机、双盲、安慰剂对照研究。
住院部为城市教学医院内科病房;门诊部为该医院附属哮喘诊所。
40名年龄在18至55岁之间、因哮喘急性发作需住院治疗的患者。
在静脉注射八剂皮质类固醇后,与单独使用全身用皮质类固醇相比,通过定量吸入器吸入氟尼缩松(每次激活250微克),每日两次,每次八喷。
在第1天(到急诊科就诊时)和第7天门诊随访时记录呼气峰值流速(PEFR)、第1秒用力呼气量(FEV₁)和症状评分。从第1天到第7天,氟尼缩松组的平均PEFR从190升/分钟增至379升/分钟,全身用皮质类固醇组从207升/分钟增至347升/分钟(p = 0.95;95%置信区间[CI],-66.3,无穷大)。氟尼缩松组的平均FEV₁从1.6升增至2.3升,全身用皮质类固醇组从1.4升增至2.1升(p = 0.33;95% CI,-21.7,无穷大)。氟尼缩松组症状评分变化为-0.7,全身用皮质类固醇组为-0.9(p = 0.39;95% CI,-0.4,无穷大)。两组在第7天的再住院率均为零。
对于因严重哮喘住院的患者,在住院后的7天内,高剂量吸入皮质类固醇与全身用皮质类固醇同样有效。